Drug Profile
Research programme: antiviral vaccines - Cytos Biotechnology/VECTORIE
Latest Information Update: 13 May 2014
Price :
$50
*
At a glance
- Originator Cytos Biotechnology
- Developer Cytos Biotechnology; VECTORIE
- Class Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Viral infections
Most Recent Events
- 13 May 2014 Research programme: antiviral vaccines - Cytos Biotechnology/VECTORIE is available for licensing as of 05 May 2014. http://www.cytos.com
- 18 Aug 2011 Suspended for Viral infections in France (unspecified route)
- 21 Feb 2011 Early research in Viral infections in France (unspecified route)